Compare Liberty Global Ltd Class C (LBTYK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs BIO-TECHNE Corp — how do they compare? Liberty Global Ltd Class C trades at $8.43 (market cap $3.06B), while BIO-TECHNE Corp trades at $72.5 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 3.7× Liberty Global Ltd Class C's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and BIO-TECHNE Corp for 64 Days on average.
| LBTYK | TECH | |
|---|---|---|
Market Cap | $3.06B | $11.36B |
Volume | 2,508,956 | 5,390,331 |
Sector | Media | Health |
52-Week High | $12.67 | $72.61 |
52-Week Low | $8.75 | $43.31 |
Typical Hold Time | 21 Days | 64 Days |
Enterprise Value | $9.72B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LBTYK trades at $8.65, down 3.03% today and near 52-week lows. The stock shows bearish technical signals with negative earnings trends, including a Q3 2026 net loss of -$3.0B. However, strong analyst support (69% buy ratings) and a $12.67 price target suggest potential upside. Recent developments include the Ziggo Group spin-off preparation and AI partnership with Sierra.
The outlook remains cautious due to persistent losses and bearish technicals, but strategic moves like Ziggo's 2027 listing and solid cash flow ($602M net in 2026) offer recovery potential. Key risks include execution challenges and competitive pressures, while institutional sentiment provides a floor for valuation.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
